Modalis Therapeutics Corp
TSE:4883
Modalis Therapeutics Corp
TSE:4883
Price:
58
JPY
1.75%
Market Closed
Market Cap:
¥5.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Modalis Therapeutics Corp
TSE:4883
|
JP |
|
Gunze Ltd
TSE:3002
|
JP |
|
Lung Ming Green Energy Technology Engineering Co Ltd
TWSE:3018
|
TW |
|
One REIT Inc
TSE:3290
|
JP |
|
T
|
Tenaga Nasional Bhd
KLSE:TENAGA
|
MY |
|
A
|
Alpha Metallurgical Resources Inc
NYSE:AMR
|
US |
|
E
|
Epicon Bhd
KLSE:EPICON
|
MY |
|
AP Memory Technology Corp
TWSE:6531
|
TW |
|
Incannex Healthcare Ltd
ASX:IHL
|
AU |
|
S
|
Superdry PLC
SWB:49S
|
UK |
|
Taiyo Yuden Co Ltd
TSE:6976
|
JP |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
US |
Income Statement
Earnings Waterfall
Modalis Therapeutics Corp
Modalis Therapeutics Corp
Income Statement
Modalis Therapeutics Corp
Modalis Therapeutics Corp
Currency: JPY
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
1
|
2
|
3
|
5
|
5
|
5
|
5
|
5
|
4
|
4
|
4
|
4
|
4
|
4
|
0
|
0
|
0
|
|
| Revenue |
342
N/A
|
330
-4%
|
6
-98%
|
3
-49%
|
1
-65%
|
41
+3 627%
|
41
-1%
|
41
N/A
|
41
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(740)
|
(864)
|
(921)
|
(911)
|
(1 241)
|
(1 497)
|
(1 673)
|
(2 043)
|
(2 104)
|
(2 111)
|
(2 240)
|
(2 234)
|
(2 371)
|
(2 346)
|
(2 165)
|
(1 824)
|
(1 338)
|
(1 494)
|
(1 531)
|
(2 090)
|
(2 212)
|
|
| Selling, General & Administrative |
(208)
|
(230)
|
(244)
|
(234)
|
(231)
|
(227)
|
(232)
|
(234)
|
(242)
|
(248)
|
(250)
|
(262)
|
(268)
|
(264)
|
(252)
|
(240)
|
(245)
|
(239)
|
(249)
|
(248)
|
(232)
|
|
| Research & Development |
(532)
|
(452)
|
(494)
|
(494)
|
(1 010)
|
(1 268)
|
(1 439)
|
(1 807)
|
(1 862)
|
(1 863)
|
(1 989)
|
(1 973)
|
(2 103)
|
(2 082)
|
(1 913)
|
(1 583)
|
(1 092)
|
(1 241)
|
(1 282)
|
(1 843)
|
(1 980)
|
|
| Other Operating Expenses |
(0)
|
(183)
|
(183)
|
(183)
|
(0)
|
(2)
|
(2)
|
(2)
|
0
|
(0)
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
(14)
|
0
|
0
|
(0)
|
|
| Operating Income |
(398)
N/A
|
(535)
-34%
|
(914)
-71%
|
(908)
+1%
|
(1 239)
-37%
|
(1 456)
-17%
|
(1 633)
-12%
|
(2 002)
-23%
|
(2 063)
-3%
|
(2 111)
-2%
|
(2 240)
-6%
|
(2 234)
+0%
|
(2 371)
-6%
|
(2 346)
+1%
|
(2 165)
+8%
|
(1 824)
+16%
|
(1 338)
+27%
|
(1 494)
-12%
|
(1 531)
-2%
|
(2 090)
-37%
|
(2 212)
-6%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
(5)
|
2
|
12
|
16
|
11
|
28
|
87
|
120
|
72
|
54
|
36
|
19
|
35
|
62
|
44
|
(21)
|
61
|
8
|
(36)
|
22
|
12
|
|
| Non-Reccuring Items |
0
|
486
|
486
|
486
|
484
|
0
|
0
|
0
|
(712)
|
(734)
|
(749)
|
(750)
|
(39)
|
(17)
|
(2)
|
(1)
|
(14)
|
0
|
(14)
|
(16)
|
(3)
|
|
| Total Other Income |
(36)
|
(36)
|
(31)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(4)
|
(5)
|
(6)
|
(9)
|
(16)
|
(15)
|
(15)
|
(24)
|
(26)
|
(25)
|
25
|
26
|
52
|
|
| Pre-Tax Income |
(440)
N/A
|
(83)
+81%
|
(449)
-443%
|
(407)
+9%
|
(745)
-83%
|
(1 429)
-92%
|
(1 547)
-8%
|
(1 884)
-22%
|
(2 707)
-44%
|
(2 795)
-3%
|
(2 959)
-6%
|
(2 973)
0%
|
(2 391)
+20%
|
(2 316)
+3%
|
(2 138)
+8%
|
(1 869)
+13%
|
(1 317)
+30%
|
(1 511)
-15%
|
(1 556)
-3%
|
(2 058)
-32%
|
(2 151)
-5%
|
|
| Net Income | ||||||||||||||||||||||
| Tax Provision |
(9)
|
(46)
|
(9)
|
(9)
|
6
|
50
|
14
|
16
|
4
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
|
| Income from Continuing Operations |
(448)
|
(128)
|
(458)
|
(416)
|
(739)
|
(1 380)
|
(1 532)
|
(1 867)
|
(2 703)
|
(2 796)
|
(2 960)
|
(2 975)
|
(2 392)
|
(2 317)
|
(2 140)
|
(1 870)
|
(1 318)
|
(1 512)
|
(1 557)
|
(2 059)
|
(2 153)
|
|
| Net Income (Common) |
(448)
N/A
|
(128)
+71%
|
(458)
-257%
|
(416)
+9%
|
(739)
-78%
|
(1 380)
-87%
|
(1 532)
-11%
|
(1 867)
-22%
|
(2 703)
-45%
|
(2 796)
-3%
|
(2 960)
-6%
|
(2 975)
0%
|
(2 392)
+20%
|
(2 317)
+3%
|
(2 140)
+8%
|
(1 870)
+13%
|
(1 318)
+30%
|
(1 512)
-15%
|
(1 557)
-3%
|
(2 059)
-32%
|
(2 153)
-5%
|
|
| EPS (Diluted) |
-17.02
N/A
|
-4.23
+75%
|
-15.94
-277%
|
-15.93
+0%
|
-25.7
-61%
|
-47.54
-85%
|
-52.66
-11%
|
-64.11
-22%
|
-92.85
-45%
|
-93.79
-1%
|
-99.51
-6%
|
-95.34
+4%
|
-77.24
+19%
|
-68.67
+11%
|
-57.35
+16%
|
-40.79
+29%
|
-28.57
+30%
|
-20.9
+27%
|
-20.55
+2%
|
-26.42
-29%
|
-27.86
-5%
|
|
Switch to:
Switch to:
See Also
Discover More
